Why did a multi-cancer blood test fail?

Multi-cancer blood test doesn’t cut late-stage diagnoses

Results presented at an oncology meeting in Chicago found that the Galleri multi-cancer blood test—marketed as a way to detect more than 50 types of cancer—did not meet its main goal in a large trial involving NHS patients.

In the study, about 142,000 participants were tested using the screening approach. Despite the scale of the trial, the blood test failed to reduce late-stage cancer diagnoses, which is the outcome most directly tied to whether earlier detection translates into better timing of care.

Why that matters is practical: a screening test’s value depends not just on whether it can flag cancers, but on whether those findings actually shift patients toward earlier stages where treatment is more likely to be effective. When a screening tool does not achieve that stage-shifting impact, it raises concerns about benefits that would justify routine use.

The reports describe the Galleri test as intended to look for multiple cancers from a single sample, but in this randomized evaluation it did not achieve the primary aim.

For clinicians and patients, the key implication is that evidence from this large NHS trial does not support the test’s effectiveness for improving timing of diagnosis at the population level.

For policymakers and health systems, the finding is also relevant to decisions about investment, pathways for confirmatory testing after positive screens, and how to balance screening experimentation against established screening programs.

Overall, the trial’s headline result is that the test did not deliver measurable reductions in late-stage diagnoses despite a very large cohort.